ALLMedicine™ Exfoliative Dermatitis Center
Research & Reviews 42 results
https://emedicine.medscape.com/article/1053325-overview
Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...
http://emedicine.medscape.com/article/1053325-overview
Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...
https://emedicine.medscape.com/article/1053325-print
Mar 15th, 2022 - Practice Essentials Staphylococcal scalded skin syndrome (SSSS) is a toxin-mediated exfoliative dermatitis. Toxin-mediated staphylococcal syndromes comprise a group of blistering skin diseases, ranging in severity from localized bullous impetigo t...
https://emedicine.medscape.com/article/762236-overview
Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...
https://emedicine.medscape.com/article/762236-print
Jun 22nd, 2021 - Practice Essentials Exfoliative dermatitis is characterized by generalized erythema with scaling or desquamation affecting at least 90% of the body surface area. Systemic derangements may occur with exfoliative dermatitis, including peripheral ede...
Drugs 313 results see all →
Clinicaltrials.gov 2 results
https://clinicaltrials.gov/ct2/show/NCT02271724
May 16th, 2016 - Chronic inflammatory peripheral neuropathies are characterized by progressive deterioration in muscle strength, loss of sensibility, diminished or absent reflexes and impaired fine motor control. Often it is caused by demyelination which is suitab...
https://clinicaltrials.gov/ct2/show/NCT00748319
Aug 22nd, 2012 - Background : The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. Both are due to the proliferation of a CD4+ T-cell clone in the skin, associated with a blood involvement in Sezary syndrome. Mycosis fungoid...
News 7 results
https://www.onclive.com/view/eu-approves-midostaurin-for-aml-advanced-systemic-mastocytosis
Nov 13th, 2020 - Bruno Strigini, CEO The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia (AML) and advanced systemic mastocytosis (SM), including aggressive systemic mastocytosis (SM), SM ...
https://www.mdedge.com/hematology-oncology/article/203812/gynecologic-cancer/fda-approves-bevacizumab-bvzr-several-cancers
Laura Nikolaides
Jun 28th, 2019 - The Food and Drug Administration has approved bevacizumab-bvzr (Zirabev) – a biosimilar to bevacizumab (Avastin) – for the treatment of five cancers: metastatic colorectal cancer (mCRC); unresectable, locally advanced, recurrent or metastatic non-.
https://www.mdedge.com/chestphysician/article/147160/gastroenterology/fda-approves-biosimilar-bevacizumab
Laura Nikolaides, MDedge News
Sep 14th, 2017 - The Food and Drug Administration has approved a biosimilar to bevacizumab (Avastin) for the treatment of certain colorectal, lung, brain, kidney, and cervical cancers. Bevacizumab-awwb is the first biosimilar approved in the United States for the.
https://www.medscape.com/viewarticle/885684
Sep 14th, 2017 - The US Food and Drug Administration (FDA) has approved the first biosimilar for use in oncology ― the product is Mvasi (bevacizumab-awwb), from Amgen. It is equivalent to the reference product, Avastin (Genetech/Roche), which was first approved in...
https://www.mdedge.com/dermatology/article/132728/nonmelanoma-skin-cancer/imatinib-mesylate-induced-lichenoid-drug-eruption
Erin H. Penn, MD, Hye Jin Chung, MD et. al.
Mar 6th, 2017 - Imatinib mesylate is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). The indications for imatinib have expanded since its initial approval.